[1] 田金徽, 陈耀龙, 杨克虎,等. SR/MA研究进展与挑战[J]. 兰州大学学报(医学版), 2016, 42(1):42-47. [2] Petticrew M. Systematic reviews from astronomy to zoology: myths and misconceptions. [J]. Bmj, 2001, 322(7278):98-101. [3] 韦当,王琪,孙丽娜,等.从循证决策到知证决策[J].甘肃科技, 2013, 29(17):139-140. [4] 李思源, 季婷, 拜争刚,等. 循证实践在我国社会科学领域的研究现状分析[J].中国社会医学杂志, 2017, 34(6):529-532. [5] Levac D, Colquhoun H, O’Brien KK. Scoping studies: advancing the methodology. Implement Sci, 2010, 5(1): 69. [6] Arksey H, O''Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol, 2005, 8(1): 19-32. [7] 卞薇, 陈慧, 宋国敏,等. 概况性评价简介[J]. 中国循证医学杂志, 2017(4):488-493. [8] Daudt HM, van Mossel C, Scott SJ. Enhancing the scoping study methodology: a large, inter-professional team''s experience with Arksey and O''Malley''s framework. BMC Med Res Methodol, 2013, 13(1): 48. [9] Tricco AC, Lillie E, Zarin W, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation [J]. Annals of internal medicine, 2018. [10] Suhonen R, Stolt M, Habermann M, et al. Ethical elements in priority setting in nursing care: A scoping review [J].Int J Nurs Stud,2018,88:25-42 [11] 张珺, 葛龙, 赵晔,等. PRISMA系列报告规范简介[J]. 中国药物评价, 2015(5):257-261. [12] 赵晔, 葛龙, 张珺,等. 单个病例数据系统评价/Meta分析优先报告条目简介[J]. 中国药物评价, 2015(5):262-265. [13] 田金徽, 葛龙, 赵晔,等. 网状Meta分析优先报告条目:PRISMA扩展声明解读[J]. 中国药物评价, 2015(5):266-272. [14] Moher D, Schulz K F, Simera I, et al. Guidance for developers of health research reporting guidelines[J]. Plos Medicine, 2010, 7(2): e1000217. 田金徽, 葛龙, 赵晔,等. 网状Meta分析优先报告条目:PRISMA扩展声明解读[J]. 中国药物评价, 2015(5):266-272.
|